Clinical Trials Logo
  1. Home
  2. Branch Retinal Vein Occlusion
  3. NCT01599650

Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion — BRIGHTER  

Branch Retinal Vein Occlusion Clinical Trial

Official title:
A 24-month, Phase IIIb, Open-label, Randomized, Active Controlled, 3-arm, Multicenter Study Assessing the Efficacy and Safety of an Individualized, Stabilization-criteria-driven PRN Dosing Regimen With 0.5-mg Ranibizumab Intravitreal Injections Applied as Monotherapy or With Adjunctive Laser Photocoagulation in Comparison to Laser Photocoagulation in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

Clinical Trial Summary

This study will generate comparative data for 0.5-mg ranibizumab using PRN dosing administered with or without adjunctive laser treatment versus laser photocoagulation (the current standard of care) up to Month 6 in patients with visual impairment due to ME secondary to BRVO. Additionally the results of this study will provide long-term (24-month) safety and efficacy data for ranibizumab, administered with or without adjunctive laser treatment in this indication.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01599650
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 3
Start date May 2012
Completion date May 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Active, not recruiting NCT04120311 - Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole Phase 1
Not yet recruiting NCT04601688 - Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. N/A
Completed NCT01968239 - Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT Phase 2
Completed NCT00612261 - Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion N/A
Not yet recruiting NCT03637283 - Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage N/A
Completed NCT01976338 - Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) Phase 3
Completed NCT01471691 - Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab Phase 1/Phase 2
Completed NCT01247220 - REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study Phase 2
Terminated NCT00642226 - Combined Vitrectomy and Triamcinolone in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) Phase 3
Terminated NCT05127525 - EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN) Phase 3
Active, not recruiting NCT04120636 - Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole Phase 1
Recruiting NCT01975103 - Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases Phase 2
Recruiting NCT01348633 - Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye N/A
Completed NCT04740905 - A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion Phase 3
Recruiting NCT02527733 - Retinal Sensitivity in BRVO After Anti-VEGF Therapy Phase 4
Completed NCT01396057 - Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO) Phase 3
Terminated NCT03802630 - Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion Phase 3
Completed NCT02478515 - Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion Phase 4
Terminated NCT01795209 - Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision Phase 4